Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1537-1546

  Muduma, Gorden ^a   Shaw, Jane ^a   Hart, Warren M ^b   Odeyemi, Abayomi ^b   Odeyemi, Isaac ^a  

^a Astellas Pharma Europe Ltd   (United Kingdom)

^b Ecostat consulting UK limited   (United Kingdom)

Author keywords

Cost effectiveness; Costs; Great Britain; Tacrolimus

Indexed keywords

BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; DIALYSIS; DRUG FORMULATION; ECONOMIC EVALUATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMEDIATE RELEASE FORMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PATIENT COMPLIANCE; PROBABILITY; QUALITY OF LIFE; RETRANSPLANTATION; RISK FACTOR; SENSITIVITY ANALYSIS; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 84908668090     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S69461     Document Type: Article

References (30)

1. Levey AS, Eckardt KU, Tsukamoto Y, et al. Defnition and classif-cation of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089–2100.
2. Eknoyan G. Chronic kidney disease defnition and classifcation: no need for a rush to judgment. Kidney Int. 2009;75(10):1015–1018.
3. Abdel-Kader K, Unruh ML, Weisbod SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057–1064.
4. National Institute for Clinical Excellence [homepage on the Internet]. Immunosuppressive therapy for renal transplantation in adults. Technical Appraisal 85, September 2004. Available from: www.nice.org.uk/TA85. Accessed March 3, 2014.
5. Opelz G, Döhler B; Collaborative Transplant Study Report. Infuence of time of rejection on long-term graft survival in renal transplantation. Transplantation. 2008;85(5):661–666.
6. McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosup-pression following renal transplantation in the UK. Pharmacoeconom-ics. 2006;24(1):67–79.
7. Organ Donation and Transplantation. Activity Report 2012/13. Available from: http://www.organdonation.nhs.uk/statistics/transplant_activity_report/archive_activity_reports/pdf/ukt/activity_report_2012_13.pdf. Accessed March 1, 2014.
8. UK Renal Registry [homepage on the Internet]. UK Renal Registry 15th Annual Report: Chapter 5 Survival and Cause of Death of Adult Patients on Renal Replacement Therapy in 2011: National and centre-specifc analyses. Available from: http://www.renalreg.com/Reports/2012.html. Accessed March 3, 2014.
9. National Institute for Health and Care Excellence [homepage on the Internet]. The guidelines manual 2012; November 2012. Available from: http://www.nice.org.uk/guidance/pmg6. Accessed March 3, 2014.
10. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. Available from: http://www.cadth.ca/en/products/health-technology-assessment/publication/884. Accessed September 16, 2014.
11. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tac-rolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331(7520):810–820.
12. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81(9):1234–1248.
13. Jürgensen JS, Arns W, Hass B. Cost-effectiveness of immunosup-pressive regimens in renal transplant recipients in Germany: a model approach. Eur J Health Econ. 2010;11(1):15–25.
14. Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin. 2005;21(11):1777–1783.
15. Silva HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3): 595–608.
16. British National Formulary [homepage on the Internet]. BNF 66. BMJ Group, 2013. Available from: http://www.bnf.org. Accessed February 3, 2014.
17. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2): 333–340.
18. Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Prefer Adherence. 2014;8:391-399.
19. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1691.
20. Kramer B, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010;10(12):2632-2643.
21. National Institute for Health and Clinical Excellence [homepage on the Internet]. Peritoneal dialysis in the treatment of stage 5 chronic kidney disease. NICE clinical guideline 125; July 2011. Available from: http://www.nice.org.uk/guidance/cg125. Accessed March 3, 2014.
22. Rate Infation [homepage on the Internet]. Consumer price index. Available from: http://www.rateinfation.com. Accessed March 3, 2014.
23. National Institute for Health and Care Excellence [homepage on the Internet]. Guide to the methods of technology appraisal; April 2013. Available from: http://www.nice.org.uk/guidance/pmg9. Accessed March 3, 2014.
24. Offce of national statistics [homepage on the Internet]. National Life tables, 2010-2012 available from: http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-325699. Accessed March 3, 2014.
25. All Wales Medicines Strategy Group [homepage on the Internet]. AWMSG secretariat assessment report - Advice No. 1712 Belatacept (Nulojix®V) 250 mg powder for concentrate for solution for infusion; May 2012. Available from: http://www.awmsg.org/awmsgonline/app/appraisalinfo/430. Accessed August 14, 2014.
26. Gamboa O, Montero C, Mesa L, et al. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation. Transplant Proc. 2011; 43(9):3367-3376.
27. Rely K, Galindo-Suarez R, Alexandre P, et al. Cost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in Mexico. Value in Health Regional Issues. 2012; 1: 211-217.
28. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-2575.
29. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876-1885.
30. Davies C, Briggs A, Lorgelly P, Garellick G, Malchau H. The “hazards” of extrapolating survival curves. Med Decis Making. 2013;33(3): 369-380.